canertinib dihydrochloride and its Impurities

Canertinib Dihydrochlorideis an irreversible tyrosine-kinase inhibitor with activity against EGFR HER-2 and ErbB-4 By 2015, Pfizer had discontinued development of the drug. It is an experimental drug candidate for the treatment of cancer. Canertinib Dihydrochloride has been reported as a substrate for OATP1B3.. Reference standards of Canertinib Dihydrochloride API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below